Facebook Twitter LinkedIn Google Plus RSS

J&J says it sells final stake in Elan for $332M Source: Bloomberg

Johnson & Johnson sold 25.4 million shares of Elan Corp. ending a relationship started four years ago to develop the Alzheimer's disease drug bapineuzumab.

Continue Reading »»

You May Have Missed...

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy